Does this accounting review imply that Steve and Fran can no longer be relied upon? With pockets stuffed with money, where are they taking this shell?
Sense of humor? Fran and Steve have left SDIX investors with little else. I wonder if the delay has to do with other offers, possibilities for Life Science. Whatever became of Padgett and NovusBio?
Let's see, they got 4.5 million for water test kits, 13.5 millions for food safety, and 16 million for antibodies. I suppose we remain in limbo until Becker decides what to do with the money!
If management were only more forthright with their plans, we wouldn't be so cynical of their intentions. Like Klaus, Fran slips out the backdoor without a peep.
Perhaps SDIX have patents or other intellectual properties that can generate royalties from Origene's future antibodies sales(Does this sale leave Novusbio and Karen Padgett out of the picture?). Becker and DiNuzzo have not been forthright with their investors, and all we can do is speculate about any future for SDIX.
for shareholders is a stock price of a dollar and a few pennies! Steven Becker, with the sale of antibodies production, what do you and DiNuzzo have up your riverboat gambling sleeves? What do you intend to do with the monies from the sales of test kits and life science? Like mushrooms, SDIX investors are being kept in the dark.
for basically what money they had in the rabbit/mice antibodies collection facilities. Their science, as a previous post pointed out, got squat! No wonder Klaus jumped ship in September. Was board member Steve Becker a facilitator in this transaction, covering his lost with a vested interest in Origene? Inquiring minds would like to know!
Fire sale. Is Origene a privately held company? With a substantial investment, maybe Becker was the facilitator in this deal.
What major holder is selling today? Becker, T.RowePrice, mutual fund?
The last three CEO's, attempting to represent this corporation, should have, not souvenir, but legitimate baseball bats pegged up their #$%$!
_______________ fill in the blank